Clinical Trial Update: Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial assessing the safety and efficacy of autologous alpha-2 macroglobulin rich plasma for symptomatic moderate knee osteoarthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Knee Osteoarthritis
• Osteoarthritis

Drugs mentioned

• Autologous Alpha-2 Macroglobulin Rich Plasma (autologous alpha-2 macroglobulin rich plasma)

Snippet

Sponsor: Mayo Clinic | Conditions: Osteoarthritis, OA | Phase 1, Phase 2 | Status: COMPLETED